SOLENO THERAPEUTICS INC
SLNOUnited States
51 filed reports · 591 financial concepts
Latest figures
Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.
| Figure | Latest fiscal year | Latest quarter |
|---|---|---|
| Revenue | $190MFY2025 · to Dec 31, 202510-K | $94.6MQ1 FY2026 · to Mar 31, 202610-Q |
| Net income | $20.9MFY2025 · to Dec 31, 2025a year earlier: -$176M10-K | $31.4MQ1 FY2026 · to Mar 31, 2026a year earlier: -$43.8M10-Q |
| Operating income | $9.41MFY2025 · to Dec 31, 2025a year earlier: -$188M10-K | $31.3MQ1 FY2026 · to Mar 31, 2026a year earlier: -$45.7M10-Q |
Filed reports
51 reports · Jun 2015 to Mar 2026Each report counts once it has at least one extracted financial fact.
| Report type | Reports | Facts | Periods |
|---|---|---|---|
| Quarterly · 10-QSEC EDGAR | 32 | 3,089 | Jun 2015 to Mar 2026 |
| Annual · 10-KSEC EDGAR | 11 | 3,156 | Dec 2015 to Dec 2025 |
| Registration · S-1SEC EDGAR | 5 | 300 | Aug 2015 to Jan 2018 |
| Quarterly · 10-Q/ASEC EDGAR | 2 | 101 | Mar 2016 to Sep 2019 |
| Registration · S-1/ASEC EDGAR | 1 | 3 | Aug 2016 |
Documents
| Period | Type | Period end | Published | Facts | Source |
|---|---|---|---|---|---|
| FY2026 Q1 | 10-Q | Mar 31, 2026 | May 7, 2026 | 333 | Open |
| FY2025 | 10-K | Dec 31, 2025 | Feb 25, 2026 | 744 | Open |
| FY2025 Q3 | 10-Q | Sep 30, 2025 | Nov 4, 2025 | 206 | Open |
| FY2025 Q2 | 10-Q | Jun 30, 2025 | Aug 6, 2025 | 161 | Open |
| FY2025 Q1 | 10-Q | Mar 31, 2025 | May 7, 2025 | 106 | Open |
| FY2024 | 10-K | Dec 31, 2024 | Feb 28, 2025 | 249 | Open |
| FY2024 Q3 | 10-Q | Sep 30, 2024 | Nov 6, 2024 | 112 | Open |
| FY2024 Q2 | 10-Q | Jun 30, 2024 | Aug 7, 2024 | 110 | Open |
| FY2024 Q1 | 10-Q | Mar 31, 2024 | May 9, 2024 | 88 | Open |
| FY2023 | 10-K | Dec 31, 2023 | Mar 7, 2024 | 129 | Open |
| FY2023 Q3 | 10-Q | Sep 30, 2023 | Nov 8, 2023 | 92 | Open |
| FY2023 Q2 | 10-Q | Jun 30, 2023 | Aug 8, 2023 | 71 | Open |
Financial data
591 concepts · 6,649 factsEach concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.
Financial590 concepts · 6,647 facts · Dec 2013 to Mar 2026
- Cash and cash equivalents at carrying value63 · Dec 2013 to Mar 2026
- Allocated share based compensation expense62 · Dec 2013 to Mar 2026
- Depreciation and amortization62 · Dec 2013 to Mar 2026
- Increase decrease in accounts payable62 · Dec 2013 to Mar 2026
- Increase decrease in prepaid deferred expense and other assets62 · Dec 2013 to Mar 2026
- Net income loss62 · Dec 2013 to Mar 2026
- Operating expenses (US GAAP)62 · Dec 2013 to Mar 2026
- Operating income loss62 · Dec 2013 to Mar 2026
- Research and development expense62 · Dec 2013 to Mar 2026
- Common stock par or stated value per share61 · Dec 2013 to Mar 2026
- Common stock shares authorized61 · Dec 2013 to Mar 2026
- Accounts payable current60 · Dec 2013 to Mar 2026
- Additional paid in capital common stock60 · Dec 2013 to Mar 2026
- Assets60 · Dec 2013 to Mar 2026
- Assets current60 · Dec 2013 to Mar 2026
- Common stock shares issued60 · Dec 2013 to Mar 2026
- Common stock shares outstanding60 · Dec 2013 to Mar 2026
- Common stock value60 · Dec 2013 to Mar 2026
- Liabilities and stockholders equity60 · Dec 2013 to Mar 2026
- Liabilities current60 · Dec 2013 to Mar 2026
- Prepaid expense and other assets current60 · Dec 2013 to Mar 2026
- Property plant and equipment net60 · Dec 2013 to Mar 2026
- Retained earnings accumulated deficit60 · Dec 2013 to Mar 2026
- Stockholders equity (US GAAP)60 · Dec 2013 to Mar 2026
Product1 concept · 2 facts · Mar 2025 to Jun 2025
- Revenue2 · Mar 2025 to Jun 2025
Segments
2 factsFigures broken down by business line, region, product or another axis the company reports on.
Product or service1 member · 2 facts
- Product [Member]2 · Mar 2025 to Jun 2025
Text from filings
Management commentary and risk factors, extracted from SEC filings only.
No commentary or risk-factor text for this company.
Earnings calls
Transcripts with management claims and analyst questions, one per fiscal period.
No earnings-call transcripts for this company.
Executive media
Podcasts, interviews and conference appearances by the company's executives, with their claims.
No media appearances for this company.
Ask about this company in your AI model
Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.
Use FactIQ to get the revenue, net income and operating income of SOLENO THERAPEUTICS INC (SLNO) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.
Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 16, 2026) and refreshed every few hours.